Search clinical trials for: Hairy Cell

Total 49118 results

Stanford University
The Leukemia and Lymphoma Society

Recruiting

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Follicular Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Not yet recruiting

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Recurrent Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia Variant
Power Life Sciences Inc.

Not yet recruiting

Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients

Hairy Cell Leukemia
Esperion Therapeutics, Inc.

Recruiting

A Phase 2 Clinical Study in Children With HeFH Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

Hypercholesterolemia

United States, Spain, Denmark, Canada, Netherlands, Germany
Auckland City Hospital

Recruiting

MAnagement of Systolic Blood Pressure During Thrombectomy by Endovascular Route for Acute Ischaemic STROKE (MASTERSTROKE)

Stroke | Blood Pressure | Embolus Cerebral

New Zealand
Kite, A Gilead Company

Recruiting

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25)

Relapsed/Refractory Waldenstrom Macroglobulinemia | Relapsed/Refractory Richter Transformation | Relapsed/Refractory Burkitt Lymphoma | Relapsed/Refractory Hairy Cell Leukemia

United States, Spain, Germany, Italy, France, Netherlands, Switzerland, Austria
Scripps Health

Recruiting

Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia

Hairy Cell Leukemia

United States
MacroGenics

Recruiting

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Myelodysplastic Syndromes | Chronic Myeloid Leukemia | Classical Hodgkin Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm | Leukemia, B-cell | Leukemia, Hairy Cell | Leukemia, Acute Myeloid | Mastocytosis, Aggressive Systemic

United States
University Hospital, Strasbourg, France

Recruiting

B-cell Chronic Lymphoid Malignancies Markers (MALYZOMA-II)

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Hairy Cell Leukemia | Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia

France
National Cancer Institute (NCI)

Recruiting

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

Hairy Cell Leukemia | Hairy Cell Leukemia Variant

United States
Newave Pharmaceutical Inc

Recruiting

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Hairy Cell Leukemia | CLL/SLL

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma

Sarcoma | Metastatic Sarcoma | Recurrent Sarcoma

United States
National Cancer Institute (NCI)

Recruiting

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Hairy Cell Leukemia

United States
Ohio State University Comprehensive Cancer Center
Hairy Cell Leukemia Foundation

Recruiting

Hairy Cell Leukemia Patient Data Registry (HCL-PDR)

Leukemia, Other

United States
University of Giessen

Recruiting

Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Hairy Cell Leukemia

Germany
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Registry of Older Patients With Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Cognitive/Functional Effects | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Recruiting

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Nonmalignant Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
National Cancer Institute (NCI)

Recruiting

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Chronic Lymphocytic Leukemia (CLL) | Hairy Cell Leukemia (HCL) | Cutaneous T Cell Lymphoma (CTCL) | Non-Hodgkins Lymphoma (NHL) | Adult T Cell Lymphoma (ATL)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia | Hairy Cell Leukemia Variant

United States
Acerta Pharma BV
Merck Sharp & Dohme LLC

Active, not recruiting

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)

Multiple Myeloma | Hodgkin Lymphoma | Waldenström Macroglobulinemia | Burkitt Lymphoma | Small Lymphocytic Lymphoma (SLL) | Hairy Cell Leukemia | CLL | Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Richter's Syndrome | Indolent Non Hodgkin Lymphoma | Marginal Zone Lymphomas | Mediastinal Large B Cell...

United States
Xencor, Inc.
ICON Clinical Research

Active, not recruiting

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Chronic Lymphocytic Leukemia | B-cell Non-Hodgkins Lymphoma

United States, France, Korea, Republic of, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Yale University; Dana-Farber Cancer Institute

Active, not recruiting

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

Leukemia | Leukemia, Hairy Cell | Hairy Cell Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Recurrent Adult Burkitt Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Chronic Lymphocytic Leukemia | Recurrent Follicular Lymphoma and other conditions

United States
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA)

Follicular Lymphoma

United States, Spain, Belgium, Japan, Australia, Germany, Italy, Netherlands, Norway, United Kingdom, Austria, France
Stanford University
National Cancer Institute (NCI)

Terminated

Ipilimumab and Local Radiation for Selected Solid Tumors

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Systemic Mastocytosis | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Completed

LMB-2 to Treat Hairy Cell Leukemia

Hairy Cell Leukemia

United States
University of Nebraska
National Cancer Institute (NCI)

Completed

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease | Secondary Myelofibrosis

United States
Joseph Tuscano
National Cancer Institute (NCI); Celgene

Active, not recruiting

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Hairy Cell Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Cancer

France, Spain, Netherlands, Canada, Austria, United States, Germany, Italy, Japan, Norway, Korea, Republic of, Denmark, Sweden, Belgium
Alexey Danilov, MD
Gilead Sciences; Oregon Health and Science University

Completed

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Anemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Hairy Cell Leukemia | Richter Syndrome | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Grade 1 Follicular... and other conditions

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Northwestern University; Northwell Health; Dana-Farber... and other collaborators

Active, not recruiting

BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia

Hairy Cell Leukemia

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

Lymphoma | Leukemia

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Suspended

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia | Cutaneous B-cell Non-Hodgkin Lymphoma | Intraocular Lymphoma | Small Intestine Lymphoma | Testicular Lymphoma | B-cell... and other conditions

United States
AstraZeneca
Iqvia Pty Ltd

Terminated

US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) (PROXY)

Hairy Cell Leukemia

United States
Mustang Bio

Enrolling by invitation

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Diffuse Large B Cell Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Hairy Cell Leukemia | Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Chronic Lymphocytic Leukemia in Relapse | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma and other conditions

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent... and other conditions

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI)

Withdrawn

Collecting and Storing Blood Samples From Patients With Cancer

Lymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Nonmalignant Neoplasm | Lymphoproliferative Disorder and other conditions
Northwestern University
National Cancer Institute (NCI)

Completed

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Brain and Central Nervous System Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic Cancer | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder | Secondary...

United States
Northwestern University
Seagen Inc.

Terminated

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell... and other conditions

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States

Search clinical trials for: Hairy Cell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations